|
Diet and Nutritions > Condition Specific Supplements > Immunity Build Supplements
|
Cold-fX CVT-E002, 200 Mg Capsules - 30 ea
|
Cold-fX CVT-E002, 200 Mg Capsules are dietary supplement and provide strengthens the immune system. |
|
|
|
Email A Friend |
|
|
|
Description UPC: 027207101002 |
MANUFACTURER: COLD FX PHARAMCEUTICALS .
INDICATIONS: Cold-fX CVT-E002, 200 Mg Capsules
- Dietary Supplement.
- Strengthens the immune system.
- CBP certified, ChemBioPrint.
CVT-E002 is a proprietary and patented natural extract containing poly-furanosyl-pyranosyl-saccharides derived from Panax quinquefolius (North American Ginseng).
As a ChemBioPrint product, proprietary technology has been used to identify the active components CVT-E002, to prove the health benefit of CVT-E002, and to ensure that the product is consistently made from batch to batch.
Biological fingerprinting identifies the pharmacological effect of the components of Cold-fX on immunological function The quality assurance of precise manufacturing leads to measurable chemical and biological consistency.
DIRECTIONS: Recommended use for adults and children ages 12 years and older.
Recommended 3 day dose to strengthen the immune system:
- Day 1 - Take 3 capsules 3 times during the day (total = 9 capsules).
- Day 2 - Take 2 capsules 3 times during the day (total = 6 capsules).
-
Day 3 - Take 1 capsule 3 times during the day (total = 3 capsules). Recommended long-term dose to maintain a healthy immune system.
Take 1 capsule 2 times each day.
WARNINGS: Individuals with serious health conditions or taking other medications, or pregnant of lactating women, should consult a health care professional before taking Cold-fX extract.
As Cold-fX extract is a derivative of North American ginseng, it is not recommended for individuals with allergies to ginseng.
Do not exceed the recommended daily dose.
Image may vary from actual product due to Continuous manufacturer Product updates. Information we provide is for your reference only
|
|
Related Products
|
|
|
Add Product Review |
|
|